Navigation Links
Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
Date:12/9/2008

tality related to treatment is normally an issue when treating AML patients, there were no deaths within 7 days of treatment and 6 deaths (13%) within 30 days of receiving CPX-351. The induction mortality seen in the Phase 1 study was deemed encouraging by investigators. Major GI toxicity was uncommon with only 4 patients experiencing grade 3 or greater nausea and vomiting or mucositis.

Pharmacokinetic data collected during the study confirmed the bioavailability of cytarabine and daunorubicin, demonstrated a prolonged half-life for both drugs and their metabolites, and confirmed that the synergistic ratio was maintained for more than 24 hours after infusion.

The Phase 1 study enrolled 37 patients with advanced AML, secondary AML and ALL, during the dose-escalation phase. The maximum tolerated dose was established at 101 units/m2. An additional 10 patients were recruited and treated at this dose level to confirm tolerability and collect preliminary data on efficacy, bringing the total trial enrollment to 47. The recommended dose for Phase 2 study was determined to be 101 units/m2 given as a 90 minute infusion on treatment days 1, 3, and 5.

These findings were supported by a separate pre-clinical study that was also reported at the ASH meeting. Using a bone marrow engrafted human leukemia xenograft model, investigators compared CPX-351 with conventional cytarabine/daunorubicin treatment. The study confirmed that CPX-351, unlike the conventional combination, produced prolonged exposure of CPX-351 in the bone marrow and evidence of direct uptake of CPX-351 by leukemia cells with subsequent intracellular release of the drugs. Exposure of leukemic cells to synergistic drug ratios was confirmed.

In November, Celator announced enrollment of the first patient in a randomized Phase 2 study of CPX-351 versus conventional cytarabine and daunorubicin ("7 + 3") in patients with newly dia
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Frederick R. Appelbaum, M.D. and Ross C. Donehower, M.D. Join Scientific Advisory Board of Celator(R) Pharmaceuticals
2. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
3. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
4. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
5. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference
6. Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas
7. Memory Pharmaceuticals Receives NASDAQ Decisions
8. MAP Pharmaceuticals to Present at the 2008 RBC Capital Markets Healthcare Conference
9. The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders
10. Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
11. Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... A new type of festival is emerging in ... Tap at the Science Museum of Virginia not only fills ... hops for a bold, new flavor. , The 21+ festival ... the science behind these frothy beverages. Guests uncover the brewing ... the ingredients that go into beer with Original Gravity and ...
(Date:4/27/2015)... April 27, 2015 A variety of events ... people trapped in substance abuse. Programming for Jericho for boys ... girls, is launching this summer. , The first event is ... to serve adolescents. The Youth Town Jim Jackson Golf Classic ... Monday, May 4, with tee times at 8 a.m. and ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Moreno Ranches, ... http://www.morenoranches.com/ , is proud to announce their "This is ... interested in Brahman cattle breeding and education was a ... Florida, on April 18, 2015. It brought together ... future interest in cattle breeding in general, and Brahman ...
(Date:4/27/2015)... April 27, 2015 Jesse L. Goodman, ... United States Pharmacopeial Convention (USP) at the recently concluded ... of Medicine at Georgetown University and the Director of ... (COMPASS). , As USP President, a volunteer position, Dr. ... He will be a voting member, ex officio, of ...
(Date:4/27/2015)... "Understanding Mental Disorders: Your Guide to the ... Psychiatric Publishing, a division of the American Psychiatric Association. ... National Press Club in Washington, D.C.. The launch event ... President Paul Summergrad, MD. Guest speakers will include Former ... the book; Paul Gionfriddo, President and CEO of Mental ...
Breaking Medicine News(10 mins):Health News:Science on Tap at the Science Museum of Virginia 2Health News:Golf, Sermon on the Mount and More to Support Youth Town’s Jericho and Eden Programs 2Health News:Leading Ranch for Brahman Cattle for Sale, Moreno Ranches, Announces Conclusion of 'This is It' Event for Brahman Juniors. 2Health News:Dr. Jesse Goodman Elected President of the USP Convention 2Health News:American Psychiatric Association, Patrick Kennedy To Debut New Consumer Guidebook “Understanding Mental Disorders” 2
... of these infant medicines, not product safety, is ... the voluntary withdrawal,- This withdrawal does not affect cough and cold medicines for children ... ... for infants and,children will occur at the October 18 and 19 FDA advisory committee ...
... Oct. 11 Businesses can no longer afford ... spend more than,75 billion dollars on obesity-attributable health ... are lost to obesity-related illness each,year(2). Other costs ... and high turnover rates. Today, business leaders, ...
... * concentrated Tylenol(R) Infants, Drops Plus Cold and ... * PediaCare(R) Infant Drops ... division of McNeil-PPC, Inc., announced today that the,company is voluntarily withdrawing ... directed, these medicines are generally,recognized as safe and effective. While most ...
... and Multimedia Healthcare Communication, PARIS, October 11 ... today two key acquisitions designed to reinforce its ... acquisitions,aim at strengthening Publicis Groupe,s leadership in both ... (Salerno), a highly innovative agency, specialized in,digital communications ...
... Has,a Story," a grassroots and integrated media project celebrating babies ... to survive and thrive --,has been launched by the March ... over the country tell,a special story about the baby they ... March of Dimes. "Families can also express their,hopes and dreams ...
... SACRAMENTO, Calif., Oct. 10 The governor ... (CSU) retirees to,participate in a self-funded comprehensive vision ... the Legislature and governor have recognized,the need to ... said,Barbara LaPlante, President of CSEA Retirees, Inc. "When ...
Cached Medicine News:Health News:Makers of OTC Cough and Cold Medicines Announce Voluntary Withdrawal of Oral Infant Medicines 2Health News:Makers of OTC Cough and Cold Medicines Announce Voluntary Withdrawal of Oral Infant Medicines 3Health News:Experts Urge Businesses to 'Get Real' About Obesity Impact 2Health News:Experts Urge Businesses to 'Get Real' About Obesity Impact 3Health News:Experts Urge Businesses to 'Get Real' About Obesity Impact 4Health News:McNeil Consumer Healthcare is Voluntarily Withdrawing Infants' Cough and Cold Products: 2Health News:McNeil Consumer Healthcare is Voluntarily Withdrawing Infants' Cough and Cold Products: 3Health News:Publicis Groupe Strengthens its Leadership in Digital and Integrated Healthcare Communications in Italy 2Health News:Publicis Groupe Strengthens its Leadership in Digital and Integrated Healthcare Communications in Italy 3Health News:Publicis Groupe Strengthens its Leadership in Digital and Integrated Healthcare Communications in Italy 4Health News:'Every Baby Has a Story' Campaign Tours the Nation for March of Dimes 2Health News:Governor Signs Bill Providing Vision Care Program for State University Retirees 2
(Date:4/27/2015)... April 27, 2015  CytoSorbents Corporation (NASDAQ: ... commercializing its CytoSorb® extracorporeal cytokine adsorber to purify ... of Dr. Joerg Scheier , M.D. as ... is a specialist in intensive care medicine and ... experience in treating critically-ill patients and in the ...
(Date:4/27/2015)... Pa. , April 27, 2015  Novira Therapeutics, ... therapies for curative treatment of chronic hepatitis B virus ... data for its lead HBV core inhibitor candidate, NVR ... Association for the Study of the Liver (EASL) in ... antiviral activity of NVR 3-778 from studies performed in ...
(Date:4/27/2015)... -- BRH Medical, Ltd., today announced that ... Application (510k) with the US Food and Drug Administration ... expects feedback from the FDA during the next quarter ... FDA pre-market clearance. Additional pre-market regulatory filings are anticipated ... for BRH Medical, commented, "We are thrilled to have ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Joerg Scheier as European Medical Director 2CytoSorbents Appoints Dr. Joerg Scheier as European Medical Director 3CytoSorbents Appoints Dr. Joerg Scheier as European Medical Director 4CytoSorbents Appoints Dr. Joerg Scheier as European Medical Director 5Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 2Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 3BRH Medical, Ltd., Announces Filing of a Pre-Market Submission with the US Food and Drug Administration (FDA) for the BRH-A2 Tissue Management System 2
... ® Products is pleased to announce ... was developed to support the recent introduction of LimbO Waterproof Protectors ... Products in the United Kingdom, LimbO Waterproof Protectors enable children and ... cast or a bandage. The waterproof cover is simply slipped on ...
... CITY, Feb. 21, 2012 Genomma Lab Internacional, S.A.B. de ... a non-binding proposal to acquire all of the outstanding shares ... ) common stock for $16.60 dollars per share in cash. ... including Prestige,s net debt. Genomma,s all-cash proposal ...
Cached Medicine Technology:LimbO® Products Launches New U.S. Website 2Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 2Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 3Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 4Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 5
The Astigmatome makes precise and accurate cuts for astigmatism correction simply and safely....
The Astigmatome makes precise and accurate cuts for astigmatism correction simply and safely. The procedure can be done in the office under topical anesthesia. Template Set 10mm Set. Includes 0 - 360...
... Medtronic presents the Streamline family of ... have taken the gold standard in temporary ... that make them easy to use and ... Streamline Temporary Pacing Leads are designed to ...
... Carpentier-Edwards Classic annuloplasty rings ... of choice for more than ... to restore the anatomical size ... and to help prevent recurrent ...
Medicine Products: